» Articles » PMID: 23024265

Role of Substance P in Renal Injury During DOCA-salt Hypertension

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2012 Oct 2
PMID 23024265
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Substance P (SP), a neurokinin-1 receptor (NK-1R) agonist, is mainly produced and stored in primary sensory nerves and, upon its release, participates in cardiovascular and renal functional regulation. This study tests the hypothesis that activation of the NK-1Rs by SP occurs during hypertension induced by deoxycorticosterone (DOCA)-salt treatment, which contributes to renal injury in this model. C57BL/6 mice were subjected to uninephrectomy and DOCA-salt treatment in the presence or absence of administration of selective NK-1 antagonists, L-733,060 (20 mg/kg·d, ip) or RP-67580 (8 mg/kg·d, ip). Five weeks after the treatment, mean arterial pressure determined by the telemetry system increased in DOCA-salt mice but without difference between NK-1R antagonist-treated or NK-1R antagonist-untreated DOCA-salt groups. Plasma SP levels were increased in DOCA-salt compared with control mice (P < 0.05). Renal hypertrophy and increased urinary 8-isoprostane and albumin excretion were observed in DOCA-salt compared with control mice (P < 0.05). Periodic acid-Schiff and Masson's trichrome staining showed more severe glomerulosclerosis and tubulointerstitial injury in the renal cortex in DOCA-salt compared with control mice, respectively (P < 0.05). Hydroxyproline assay and F4/80-staining showed that renal collagen levels and interstitial monocyte/macrophage infiltration were greater in DOCA-salt compared with control mice, respectively (P < 0.05). Blockade of the NK-1R with L-733,060 or RP-67580 in DOCA-salt mice suppressed increments in urinary 8-isoprostane and albumin excretion, interstitial monocyte/macrophage infiltration, and glomerulosclerosis and tubulointerstitial injury and fibrosis (P < 0.05). Thus, our data show that blockade of the NK-1Rs alleviates renal functional and tissue injury in the absence of alteration in blood pressure in DOCA-salt-hypertensive mice. The results suggest that elevated SP levels during DOCA-salt hypertension play a significant role contributing to renal damage possibly via enhancing oxidative stress and macrophage infiltration of the kidney.

Citing Articles

Cellular metabolism of substance P produces neurokinin-1 receptor peptide agonists with diminished cyclic AMP signaling.

Kriska T, Natarajan J, Herrnreiter A, Park S, Pfister S, Thomas M Am J Physiol Cell Physiol. 2024; 327(1):C151-C167.

PMID: 38798270 PMC: 11371325. DOI: 10.1152/ajpcell.00103.2024.


Substance P Improves Renal Ischemia Reperfusion Injury Through Modulating Immune Response.

Kim D, Moon J, Kim S, Seo J, Lee Y, Jung S Front Immunol. 2020; 11:600.

PMID: 32391002 PMC: 7190869. DOI: 10.3389/fimmu.2020.00600.


Tumor Necrosis Factor Alpha Deficiency Improves Endothelial Function and Cardiovascular Injury in Deoxycorticosterone Acetate/Salt-Hypertensive Mice.

Cai R, Hao Y, Liu Y, Huang L, Yao Y, Zhou M Biomed Res Int. 2020; 2020:3921074.

PMID: 32190663 PMC: 7064859. DOI: 10.1155/2020/3921074.


The Role of Substance P in Pulmonary Clearance of Bacteria in Comparative Injury Models.

Hsieh T, Vaickus M, Stein T, Lussier B, Kim J, Stepien D Am J Pathol. 2016; 186(12):3236-3245.

PMID: 27876152 PMC: 5225288. DOI: 10.1016/j.ajpath.2016.08.014.


CXCL16 Deficiency Attenuates Renal Injury and Fibrosis in Salt-Sensitive Hypertension.

Liang H, Ma Z, Peng H, He L, Hu Z, Wang Y Sci Rep. 2016; 6:28715.

PMID: 27353044 PMC: 4926114. DOI: 10.1038/srep28715.


References
1.
Rostand S, Kirk K, Rutsky E, Pate B . Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med. 1982; 306(21):1276-9. DOI: 10.1056/NEJM198205273062106. View

2.
Nakanishi S . Mammalian tachykinin receptors. Annu Rev Neurosci. 1991; 14:123-36. DOI: 10.1146/annurev.ne.14.030191.001011. View

3.
Mundel P, Shankland S . Podocyte biology and response to injury. J Am Soc Nephrol. 2002; 13(12):3005-15. DOI: 10.1097/01.asn.0000039661.06947.fd. View

4.
Elmarakby A, Quigley J, Olearczyk J, Sridhar A, Cook A, Inscho E . Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. Hypertension. 2007; 50(6):1069-76. PMC: 2491337. DOI: 10.1161/HYPERTENSIONAHA.107.098806. View

5.
PERNOW B . Substance P. Pharmacol Rev. 1983; 35(2):85-141. View